Scientific Program

Conference Series Ltd invites all the participants across the globe to attend International Conference on Neurooncology and Neurosurgery Dubai, UAE.

Submit your Abstract
or e-mail to

events@conferenceseries.com
rohit.casper@memeetings.net
katejohnson@healthcaremeeting.com

Scientific Program Day 1
Scientific Program Day 2

Day 1 :

Keynote Forum

Ernesto Miguel Delgado Cidranes

Complutense University Madrid, Spain

Keynote: The power of magnetic stimulation in the control of pelvic floor disorders: Brainsway deep TMS therapy and BTL EMSELLA protocols

Time : 09:10-10:00

Conference Series Neurooncology Surgery 2018 International Conference Keynote Speaker Ernesto Miguel Delgado Cidranes photo
Biography:

Ernesto Delgado Cidranes MD. Ph.D. is a Spanish Anesthesiologist. Director, CEO, and Founder at Advanced Pain & Aesthetic Management Center Madrid. Editorial Board Member of Journal Pain Management and Therapy. USA AIUM Members, Reviewer and Advisor Journal of Ultrasound in Medicine, American Institute (USA), Member of Organizing Committee for World Pain Medicine Conferences. Expert in pain treatment. Chairman Department of Anesthesia and Pain Medicine, Spanish University Health Ministry. International Professor of Advanced Ultrasound. Heat Pain Unit La Milagrosa Hospital & Los Madroños Hospital Madrid Staff of Anesthesiology of Ruber Quirón Hospital Madrid He has an integrative and interdisciplinary concept in the treatment of pain.
 

Abstract:

Keynote Forum

Hischam Bassiouni

Klinikum St Marien Amberg, Germany

Keynote: Application of new techniques in neurosurgery for improving patients outcome and postoperative life quality

Time : 10:00-10:50

Conference Series Neurooncology Surgery 2018 International Conference Keynote Speaker Hischam Bassiouni photo
Biography:

Hischam Bassiouni is an Associate Professor of Neurosurgery. He is the Director of two Neurosurgical Clinics at two major academic teaching hospitals, (Klinikum Amberg and Klinikum Weiden) in Bavaria, Germany. He is also the Member of German Neurosurgical Society, European Neurosurgical Society and German Skull Base Society. He had his Neurosurgical training at University Hospital Aachen and University Hospital Essen, Germany. His neurosurgical and scientific sub-specializations include neuro-oncology, neurovascular surgery, skull base surgery and neuro-pediatric surgery. He is the first author of 13 publications in highranked Neurosurgical journals and has authored several chapters in international neurosurgical reference books.
 

Abstract:

In recent years several major technical advances particularly in the treatment of brain and spinal tumors, vascular malformations and skull base surgery have been introduced into neurosurgery. These include refinements in microsurgical techniques, microscopic fluorescent techniques (e.g. 5-ALA, ICG-angiography, etc.) for maximal safe resection of intrinsic brain tumors and treatment of aneurysms and AVMs, introduction of neuroendoscopy and routine usage of intra-operative neuromonitoring in appropriate cases. We present these latest technical advances in the field of neurooncology, for the resection of skull base lesions and for the treatment of vascular malformations demonstrating their impact on preserving neurological integrity with resultant preservation of patient’s life quality after micro neurosurgical resection of tumors (e.g. Glioma, meningioma, neurinoma/schwannomas, etc.) treatment of vascular malformations (aneurysm, AVM, cavernoma) and treatment of skull base lesions. Appropriate selection and application of these new techniques under discussion in neurosurgery has resulted in a better outcome after microsurgical treatment of brain and spinal tumors, vascular malformations and skull base lesions. This includes more radical and safer tumor resection with avoidance of new neurological deficits and with preservation of patient’s neurological integrity, prolonged life expectancy in malignant brain tumors and preservation of patient’s life quality after surgery.
 

Keynote Forum

Sawsan Abuhamdah

Al Ain University of Science and Technology, United Arab Emirates

Keynote: Vanillin attenuated behavioral impairments, neurochemical deficts in a mouse model of Alzheimer’s disease

Time : 11:20-12:10

Conference Series Neurooncology Surgery 2018 International Conference Keynote Speaker Sawsan Abuhamdah photo
Biography:

Sawsan Abuhamdah is a Jordanian Registered Pharmacist. She has completed her PhD from Durham University, UK and Postdoctoral studies from Granada Medical School, Department of Pharmacology, Spain and has won Postdoctoral Fulbright Research Award at the University of Toledo, Department of pharmacology and experimental therapeuticsSawsan Abuhamdah is a Jordanian Registered Pharmacist. She has completed her PhD from Durham University, UK and Postdoctoral studies from Granada Medical School, Department of Pharmacology, Spain and has won Postdoctoral Fulbright Research Award at the University of Toledo, Department of pharmacology and experimental therapeutics, Ohio, USA. She worked as an Associate Professor at the Faculty of Pharmacy, University of Jordan and now is currently working as a Deputy Dean, College of Pharmacy, Al Ain University of Science and Technology, Abu Dhabi, UAE. She has published many research articles in peer-reviewed journals. She is also a Member of the British Pharmacological Society (BPS), British Neuroscience Association (BNA), Sigma Phi Sigma pharmaceutical Sciences Honor Society, University of Toledo, USA, Jordan Pharmaceutical Association. She has been serving as an Editorial Board Member of reputable pharmaceutical journals., Ohio, USA. She worked as an Associate Professor at the Faculty of Pharmacy, University of Jordan and now is currently working as a Deputy Dean, College of Pharmacy, Al Ain University of Science and Technology, Abu Dhabi, UAE. She has published many research articles in peer-reviewed journals. She is also a Member of the British Pharmacological Society (BPS), British Neuroscience Association (BNA), Sigma Phi Sigma pharmaceutical Sciences Honor Society, University of Toledo, USA, Jordan Pharmaceutical Association. She has been serving as an Editorial Board Member of reputable pharmaceutical journals.

Abstract:

Background: Alzheimer's Disease (AD) is a progressive neurodegenerative disease where symptoms appear after significant neuronal loss. Current treatments for AD do not significantly alter the disease process, where they temporarily improve symptoms. In vitro data has indicated that low doses of vanillin reduce beta-amyloid aggregation and may possess cytoprotective effects. This research aims to investigate the effect of vanillin on the AlCl3 mouse model of AD and thus its possible usefulness in managing AD.

Method: Male albino mice were divided into 8 groups of 10. Each group received different treatments of AlCl3, AlCl3+vanillin (30, 60 or 120 mg kgG1 day G1), vanillin alone and control. These experiments lasted for 30 days after which animals were subjected to behavioral and neurochemical assessment. Analysis was carried out using one way analysis of variance (ANOVA) with Dunnett's post-test.

Result: Lower doses of vanillin led to improvements in behavioral and neurochemical deficits induced by AlCl3. Conversely, a high dose of vanillin caused an exaggeration in the behavioral and neurochemical deficits induced by AlCl3. Furthermore, highest dose vanillin treatment, on its own, inflicted behavioral and neurochemical deficits comparable to those caused by AlCl3.

Conclusion: It is concluded that vanillin negatively impacted cholinergic neuronal survival. Any marked benefits with lower doses of vanillin were attributed to its ability to indirectly increase synaptic acetylcholine abundance through blocking its degradation.